Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions

Journal of Virology

Volumn 70, Issue 5, 1996, Pages 2825-2831

  O'Brien, William A ^a,b   Sumner Smith, Martin ^c   Mao, S I Hua ^a,b   Sadeghi, Saeed ^a,b   Zhao, Jia Q I ^b   Chen, Irvin S Y ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NPS Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; ANTIVIRUS AGENT; GLYCOPROTEIN GP 120; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CASE REPORT; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; STRAIN DIFFERENCE; TRANSACTIVATION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0029911702     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.5.2825-2831.1996     Document Type: Article

References (67)

1. Adachi, A., E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and non-human cells transfected with an infectious molecular clone. J Virol. 59:284-291
2. Arthos, J., K. C. Deen, M. A. Chaikin, J. A. Fornwald, G. Sathe, Q. J. Sattentau, P. R. Clapham, R. A. Weiss, J. S. McDougal, C. Pietropaolo, R. Axel, A. Truneh, P. J. Maddon, and R. W. Sweet. 1989. Identification of the residues in human CD4 critical for the binding of HIV. Cell 57:469-481.
3. Arya, S. K., C. Guo, S. F. Josephs, and F. Wong-Staal. 1985. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III) Science 229:69-73.
4. Baba, M., R. Pauwels, J. Balzarini, J. Arnout, J. Desmyter, and E. DeClercq. 1988. Mechanism of the inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 85:6132-6136.
5. Batinic, D., and F. A. Robey. 1992 The V3 region of the envelope glyco-protein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J. Biol. Chem. 267:6664-6671
6. Berkhout, B., and K.-T. Jeang. 1989. trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis. J. Virol. 63:5501-5504.
7. Brand, D., K. Srinivasan, and J. Sodroski. 1995. Determinants of human immunodeficiency virus type 1 entry in the CDR2 loop of the CD4 glicoprotein. J. Virol. 69:166-171.
8. Callahan, L. N., M. Phelan, M. Mallinson, and M. A. Norcross. 1991. Dentran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J. Virol. 65:1543-1550
9. Camerini, D., and B. Seed. 1990. A CD4 domain important for HIV-mediated syncytium formation lies outside the principal virus binding site. Cell 60:747-754.
10. Cann, A. J., Y. Koyanagi, and I. S. Y. Chen. 1988. High efficiency transaction of primary human lymphocytes and studies of gene expression. Oncogene 3:123-128
11. Chesebro, B., J. Nishro, S. Ferryman, A. Cann, W. O'Brien, I. S. Y. Chen, and K. Wehrly. 1991. Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells. T-cell leukemia cells, and macrophages. J Virol. 65:5782-5789.
12. Chesebro, B., K. Wehrly, J. Nishio, and S. Ferryman. 1992. Macrophagetropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism J. Virol. 66:6547-6554.
13. Chow, Y.-K., M. S. Hirsch, D. P. Merrill, L. J. Bechtel, J. J. Eron, J. C. Kaplan, and R. T. D'Aquila. 1993. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature (London) 361:650-654.
14. + T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J. Virol. 67:1772-1777.
15. Daar, E. S., X. L. Li, T. Moudgil, and D. D. Ho. 1990. High concentrations of recombinant soluble CD4 are required to neutralize primary HIV-1 isolates. Proc. Natl. Acad Sci USA 87:6574-6578.
16. de Jong, J.-J., A. de Ronde, W. Keulen, M. Tersmette, and J. Goudsmit. 1992. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing (SI) phenotype: analysis by single amino acid substitution. J Virol. 66:6777-6780
17. de Jong, J.-J., J. Goudsmit, W. Keulen, B. Klaver, W. Krone, M. Tersmette. and A. deRonde. 1992. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity J. Virol. 66:757-765.
18. Garcia, J. V., and A. D. Miller. 1991. Serine phosphorylation independent downregulation of cell-surface CD4 by nef. Nature (London) 350:505-511.
19. Gazdar, A. F., D. N. Carney, P. A. Bunn, E. K. Russell, E. S. Jaffe, G. P. Scheeler, and J. G. Guccion. 1980 Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood 55:409-417.
20. Gershoni, J. M., G. Denisova, D. Raviv, N. I. Smorodinsky, and D. Buyaner. 1993. HIV binding to its receptor creates specific epitopes for the CD4:gp120 complex FASEB J. 7:1185-1187.
21. Groenink, M., J. P. Moore, S. Broersen, and H. Schuitemaker. 1995 Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment J Virol. 69:523-527.
22. Harrich, D., C. Hsu, E. Race, and R. B. Gaynor. 1994 Differential growth kinetics are exhibited by human immunodeficiency virus type 1 TAR mutants. J. Virol. 68:5899-5910
23. Harrop, H. A., D. R. Coombe, and C. C. Rider. 1994. Heparin specifically inhibits binding of V3 loop antibodies to HIV-1. AIDS 8:183-192.
24. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 373:123-126.
25. Hwang, S. S., T. J. Boyle, H. K. Lyerly, and B. R. Cullen. 1991 Identification of envelope V3 loop as the primary determinam of cell tropism in HIV-1 Science 253:71-74
26. Kang, C.-Y., K. Hariharan, P. L. Nara, J. Sodroski, and J. P. Moore. 1994 Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. J. Virol. 68:5854-5862
27. Root, M., I. P. M. Keet, H. V. Vos, R. E. Y. DeGoede, M. T. L. Roos, R. A. Coutinho, F. Miedema, P. T. A. Schellekens, and M. Tersmette. 1993. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Intern. Med. 118:681-688
28. Koyanagi, Y., S. Miles, R. T. Mitsuyasu, J. E. Merryl, H. V. Vinters, and I. S. Y. Chen. 1987. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236:819-822.
29. Lasky, L. A., G. Nakamura, D. H. Smith, C. Fennie, C. Shimasaki, E. Patzer, P. Berman, T. Gregory, and D. J. Capon. 1987. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor Cell 50:975-985.
30. Lynch, G., L. Low, S. Li, A. Sloane. S. Adams, C. Parish, B. Kemp, and A. L. Cunningham. 1994. Sulfated polyanions prevent HIV infection of lymphocytes but do not inhibit rnonocyte infection. J. Leukocyte Biol. 56:266-272.
31. McClure, M. O., J. P. Moore, D. F. Blanc, P. Scotting, G. M. Cook, R. J. Keynes, J. N. Weber, D. Davies, and R. A. Weiss. 1992. Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro. AIDS Res. Hum Retroviruses 8:19-26.
32. McKeating. J. A.. J. Cordell. C. J. Dean, and P. Balfe. 1992. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type 1 gp 120. Virology 191:732-742.
33. Meshcheryakova, D., S. Andreev, S. Tarasova. M. Sidorava, M. Vafina, G. Kornilaeva, E. Karamov, and R. Khaitov. 1993. CD4-derived peptide and sultated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments. Mol. Immunol. 30:993-1001.
34. Mitsuya, H., D. J. Looney, S. Kuno, R. Ueno. F. Wong-Staal, and S. Broder. 1988. Dextran sulfate suppression of viruses in the HIV family: inhibition of virus binding to CD4+ cells. Science 240:646-649.
35. Mitsuya, H., K. J. Weinhold, P. A. Furman, et al. 1985 3′- Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82:7096-7100.
36. Mosier, D. E., R. J. Gulizia, P. D. Maclsaac, B. E. Torbett, and J. A. Levy. 1993. Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science 260:689-692
37. Muller. W. E. G., T. Okamoto, P. Reuter, D. Ugarkovic, and H. C. Schroder. 1990. Functional characterization of Tat protein from human immunodeficiency virus. J. Biol. Chem. 265:3803-3808.
38. Nara, P. L., K. M. Hwang, D. M. Rausch, J. D. Lifson, and L. E. Eiden. 1989. CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle. Proc. Natl. Acad. Sci. USA 86:7139-7143.
39. O'Brien. W. A., I. S. Y. Chen, D. D. Ho, and E. S. Daar. 1992 Human immunodeficiency virus type 1 resistance to soluble CD4 is conferred by domains of gpl20 that determine cell tropism. J. Virol. 66:3125-3130.
40. O'Brien, W. A., K. Grovit-Ferbas, A. Namazi, S. Ovcak-Derzic, H.-J. Wang, J. Park, C. Yeramian, S.-H. Mao, and J. A. Zack. 1995. HIV-1 replication can be increased in peripheral blood of seropositive patients following influenza vaccination. Blood 86:1082-10449
41. O'Brien, W. A., Y. Koyanagi, A. Namazie, J.-Q. Zhao, A. Diagne, K. Idler, J. A. Zack, and I. S. Y. Chen. 1990. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domam. Nature (London) 348:69-73
42. O'Brien, W. A., A. Namazi, S.-H. Mao, H. Kalhor, J. A. Zack, and I. S. Y. Chen. 1994. Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J. Virol 68:1258-1263.
43. Olshevsky, U., E. Helseth, C. Furman, J. Li, W. Haseltine, and J. Sudroski. 1990 Identification of individual human immunodeficiency virus type 1 gp 120 amino acids important for CD4 receptor binding. J. Virol 64:5701-5707
44. Patel, M., M. Yanagishita. G. Roderiquez, D. C. Bou-Habib, T. Oraveez, V. C. Hascall, and M. A. Norcross. 1993. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res. Hum. Retroviruses 9:167-174.
45. Piatak. M., M. S. Saag, L. C. Yang, S. J. Clark, J. C. Kappes, K.-C. Luk, B. H. Hahn, G. M. Shaw, and J. D. Lifson. 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-1754.
46. Rich, E. A., I. S. Y. Chen, J. A. Zack, M. L. Leonard, and W. A. O'Brien. 1992. Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus expression. Proc. Natl. Acad. Sci. USA 87:176-183.
47. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Specter, J. Sullivan, S. Cheeseman, K. Barringer, and D. Pauletti. 1994. Nevirapinc resistance mutations of human immunodeficiency virus type 1 selected during therapy, j Virol 68:1660-1666.
48. Rosen, C. A., J. G. Sodroski, and W. A. Haseltine. 1985. The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell 41:813-823.
49. Roy, S., N. T. Parkin, C. Rosen, J. Itovitch, and N. Sonenberg. 1990 Struc-tural requirements for trans activation of human immunodeficiency virus type 1 long terminal repeat-directed gene expression by tat. importance of base pairing, loop sequence, and bulges in the tat-responsive sequence. J. Virol. 64:1402-1406
50. Rasche, J. R., K. Javaherian, C. McDanal, J. Petra, D. L. Lynn, R- Grimaila, A. J. Langlois, R. C. Gallo, L. O. Arthur, P. J. Fischinger, D. P. Bolognesi, S. D. Putney, and T. J. Matthews. 1988. Antibodies that inhibit fusion of human immunodeficiency virus-infected colls and a 24-amino acid sequence of the viral envelope. gp120. Proc. Nad. Acad. Sci. USA 84:6924-6928.
51. Saag, M. S., E. A. Emini, O. L. Laskin. J. Douglas, W. I. Lapidus, W. A. Schleif, R. J. Whitley. C. Hildebrand, V. W. Byrnes, and J- C. Kappes. 1993. A short-term clinical evaluation of L-697,661. a non-nucleoside inhibitor of HIV-1 reverse transcriptase L-697,661 Working Group N. Engl. J. Med. 329:1065-1072.
52. Sattentau, Q. J., and J. P. Moore. 1991. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding J. Exp. Med. 174:407-415.
53. Schooley, R. T., T. C. Merigan, P. Gaut, M. S. Hirsch, M. Holodniy, T. Flynn, S. Liu, R. E. Byington, S. Henochowicz, E. Gubish, D. Springs, D. Kufe, J. Schindler, A. Dawson, D. Thomas, D. L. Hanson, B. T. Liu, J. Golinello. S. Kennedy, R. Fisher, and D. D. Ho. 1990. A phase I/II escalating dose trial of recombinant soluble CD4 therapy in patients with AIDS or AIDS-related complex. Ann. Intern. Med 112:247-253.
54. Schuitemaker, H., M. Koot, N. A. Kootstra, M. W. Dercksen, R. E. Y. DeGoede. R. P. Van Steenwijk. J. M. A. Lange. S. Eeftink, J. K. M., F. Miedema, and M. Tersmette. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection, progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J Virol. 66:1354-1360.
55. Shioda, T., J. A. Levy, and C. Cheng-Mayer. 1991. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp 120 gene. Nature (London) 349:167-169.
56. Sodroski, J., R. Patarca, C. Rosen, F. Wong-Staal, and W. Haseltine. 1985. Location of the trans-activating region of the genome of human T-cell lymphotropic virus type III. Science 229:74-77.
57. 56a. Sumner-Smith, M. Unpublished data
58. Stumner-Smith. M., E. D. Blair, B. Dabek. W. Lin, P. Yungblut. E. M. Twist, and S. C. Climie. Arginine-rich oligopeptides inhibit HIV-1 TAR-dependent transactivation. Submitted for publication.
59. Sumner-Smith. M., Y. Zheng, Y. P. Zhang, E. M. Twist, and S. C. Climie. 1995. Antiherpetic activities of N-α-aceryl-nona-d-arginine amide acetate. Drugs Exp Clin. Res. 21:1-6.
60. Tersmette, M., R. A. Gruters, F. de Wolf. R. E. Y. de Goede. J. M. A. Lange. P. T. A. Schellekens, J. Goudsmit, H. G. Huisman, and F. Miedema. 1989. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol 63:2118-2125.
61. Thali, M.. C. Furman, D. D. Ho, J. Robinson. S. Tilley, A. Pinter, and J. Sodroski. 1992. Discontinuous, conserved neutralization epitopes overlapping the CD4-bindmg region of human immunodeficiency virus type 1 gp!20 envelope glycoprotein. J. Viriol. 66:5635-5641.
62. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. A. Hahn. M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 373:17-122.
63. Westervelt, P., H. E. Gendelman, and L. Ratner. 1991. Identification of a determinant within the HIV-1 surface envelope glycoprotein critical for productive infection of cultured primary monocytes. Proc. Nail. Acad Sci USA 88:3097-3101.
64. Wiiley, R. L,. T. S. Theodore, and M. A. Martin. 1994. Ammo acid substitutions in the human immunodeficiency virus type 1 gp 120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope J. Virol. 68:4409-4419.
65. Wu, F., J. Garcia. D. Sigman, and R. Gaynor. 1991. tar regulates binding of the human immunodeficiency virus trans-activatmg region RNA loop-binding protein TRP-I85. Genes Dev 5:2128-2140.
66. Yu, X., M. F. McLane. L. Ratner, W. A. O'Brien, R. Oilman, M. Essex and T. Lee. Direct killing of primary T-cetls by HIV-1. Proc. Natl. Acad. Sci. USA, in press.
67. Zack, J. A., S. J. Arrigo. S. R. Weitsman, A. S. Go, A. Haislip. and I. S. Y. Chen. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213-222.